We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Pembrolizumab is under clinical development by Merck and currently in Phase I for Kaposi Sarcoma ... Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific ...

During the call, company executives will provide an overview of Merck’s performance for the fourth quarter and outlook for 2025. Investors, journalists and the general public may access a live ...

The winner of the tournament to be co-hosted by Kenya, Tanzania and Uganda will walk away with Sh455 million ...

The company last redesigned its famous yellow emblem on a blue background in 2008 ... retailer,” the company said. The updated logo is a thicker rendition of the figure designed to resemble ...

BURLINGAME, CA, UNITED STATES, January 14, 2025 /EINPresswire / -- The Ebola Vaccine Market Report is the result of extensive research and analysis conducted by our team of experienced market ...

Analyst Daina Graybosch of Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research Report), reducing the price target to $119.00. Discover outperforming stocks and invest ...

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies ... greater expansion of oncology business” and reflects the company’s optimism around its ...

Shares of Merck & Co. Inc. MRK shed 1.32% to $99.65 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.11% to 5,842.91 ...

Several people online noted that they thought the new logo looks "exactly the same" as ... “exudes the energy” of the company and “remains a beacon that guides customers through all facets ...

According to Davis, "the breadth and the depth" of Merck's current pipeline is the most diversified in the company's recent history, with its portfolio is broadening into the cardiometabolic space ...